# A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis

> **NCT06718101** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **AbbVie** · enrollment: 83 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Lutikizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06718101
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-12-19
- **Primary completion:** 2027-05
- **Final completion:** 2027-05
- **Target enrollment:** 83 (ACTUAL)
- **Last updated:** 2026-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06718101

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06718101, "A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06718101. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*